AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021
Calquence shows durable efficacy and favourable tolerability vs. standards of care across multiple analyses in chronic lymphocytic leukaemiaNew Calquence tablet formulation will potentially expand eligible patient population with comparable efficacy and safety to current capsulesEmerging pipeline will also demonstrate promise of inducing deeper patient responses using novel combinations for hard-to-treat blood cancersAstraZeneca will present new data underscoring its commitment to transforming haematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and